Search alternatives:
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
6021
-
6022
-
6023
-
6024
-
6025
-
6026
-
6027
-
6028
Image2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF
Published 2021“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
-
6029
Image1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIFF
Published 2021“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
-
6030
Image3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF
Published 2021“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
-
6031
Peak abundances for the N-glycans which had the obvious overall changes among control subjects, moderate and severe LCMM subjects.
Published 2015“…<p>Peak3, Peak4 and Peak6 decreased, whereas Peak5 increased associated with the severity of LCMM disease. …”
-
6032
-
6033
-
6034
-
6035
-
6036
-
6037
-
6038
-
6039
A 60-year-old male with a hyperacute cardioembolic infarction fifteen hours after the onset.
Published 2020“…<b>G:</b> MTR<sub>asym</sub> spectra show decreased MTR<sub>asym</sub> (3.5ppm) or APTW signal (%) in the infarct area compared to the CNAWM. mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; FLAIR, fluid attenuated inversion recovery; DWI, diffusion-weighted imaging; ROI, region-of-interest; ADC, apparent diffusion coefficient; APTW, amide proton transfer-weighted; CEST, chemical exchange saturation transfer; CNAWM, contralateral normal-appearing white matter; S<sub>sat</sub>(ppm) and S0, the signal intensities obtained with and without selective radiofrequency saturation pulse irradiation, respectively; APT<sub>10</sub>, APT<sub>25</sub>, APT<sub>50</sub>, APT<sub>75</sub>, and APT<sub>90</sub> correspond to the 10th, 25th, 50th, 75th, and 90th percentiles of the APTW signal value within the ROI, respectively.…”
-
6040
A 59-year-old male with a subacute atherosclerotic infarction nine days after the onset.
Published 2020“…<b>G:</b> MTR<sub>asym</sub> spectra show decreased MTR<sub>asym</sub>(3.5ppm) or APTW signal (%) in the infarct area compared to the CNAWM. mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; FLAIR, fluid attenuated inversion recovery; DWI, diffusion-weighted imaging; ROI, region-of-interest; ADC, apparent diffusion coefficient; APTW, amide proton transfer-weighted; CEST, chemical exchange saturation transfer; CNAWM, contralateral normal-appearing white matter; S<sub>sat</sub> (ppm) and S<sub>0</sub>, the signal intensities obtained with and without selective radiofrequency saturation pulse irradiation, respectively; APT<sub>10</sub>, APT<sub>25</sub>, APT<sub>50</sub>, APT<sub>75</sub>, and APT<sub>90</sub>, correspond to the 10th, 25th, 50th, 75th, and 90th percentiles of APTW signal value, respectively.…”